Amarantus Bioscience Holdings Inc. (AMBS … – InvestorsHub

Posted: July 31, 2015 at 8:49 pm

(AMBS) Amarantus BioScience Holdings, Inc. Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The company has licensedEltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia. The company has an exclusive worldwide license to the Lymphocyte Proliferation test("LymPro Test") is adiagnostic blood test for Alzheimers disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy.(MANF) is a human growth factor that plays a key role in the prevention of apoptosis (cell death). It is being developed for the potential treatment of RP, Parkinson's disease, Wolfram syndrome, diabetes, Alzheimer's disease and traumatic brain injury. Amarantus is a Founding Member of the Coalition for Concussion Treatment(#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease("NuroPro")and the discoveryof neurotrophic facotrs("PhenoGuard"). ESS, previously known as PermaDermisbeing developed to be theonly tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundredtimes its size in as little asthirty days.

MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis MSPrecise is a lab-developed test, and the successful completion of the validation study paves the way for this clinically important test to be commercialized in 2015. For further information, please visitwww.Amarantus.com,or connect withthecompany inFacebook,Twitter,LinkedIn&Google+

Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification of Relapsing-Remitting Multiple Sclerosis (RRMS) in the Journal GENE JULY 29, 2015 Amarantus BioScience Initiation of coverage Building up therapeutics assets July 27, 2015 Amarantus Diagnostics Establishes Strategic Advisory Committee-Advisors Bring Over 30 Years of Expertise in Successfully Commercializing Molecular Diagnostics Companies July 27, 2015 SeeThruEquity Initiates Coverage on Amarantus BioScience Holdings, Inc. with a Price Target of $45.34 JULY 24, 2015 Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-For-Purpose Use in Clinical Trials at the 2015 Alzheimer's Association International Conference(R) July 22, 2015 Amarantus Announces First Patient Dosed in Eltoprazine Phase 2b Study for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia JULY 20, 2015 Amarantus Closes Cutanogen Acquisition By Jason Napodano, CFA - Wednesday, July 15, 2015 Amarantus Completes Acquisition of ESS From Lonza for the Treatment of Severe Burns - Amarantus Now Has Full Ownership of Cutanogen Corporation, Which Has Exclusive Worldwide License to Orphan Drug Product Candidate Engineered Skin Substitute (ESS) - July 15, 2015 Amarantus to Commence Trading on the OTCQX Marketplace Under Existing Ticker Symbol AMBS-Company Progressing Toward a National Stock Exchange Listing. -July 13, 2015 Amarantus Announces Issuance of United States Patent No. 9,066,903 Covering Proprietary Methods of Administration of Eltoprazine for the Treatment of Parkinson's Disease - Patent Provides IP Protection for Lead Product Candidate Eltoprazine for the Treatment of Parkinson's Disease - June 30, 2015 Amarantus Sets Sights On NASDAQ Jason Napodano, CFA - May 29, 2015 Amarantus Enters Into CRO Agreement With Chiltern International to Commence Phase 2b Clinical Development of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia- Company Completes Investigator Meetings in U.S. and E.U. in Preparation for Study Launch - Enrollment and Dosing for 60-Patient PD-LID Study on Track to Commence 2Q 2015 May 21, 2015 Amarantus Reports First Quarter 2015 Financial Results and Business Overview- Eltoprazine Phase 2b clinical program on track to commence in 2Q 2015 - May 20, 2015 Amarantus Announces Successful Delivery and Distribution of MANF in Preclinical Model to Brain Areas Involved in Parkinson's Disease-Demonstrated MANF Can be Precisely Delivered to Parkinson's-Associated Brain Areas. May 15, 2015 MANF Begins its March Towards the Clinic May 14th, 2015 Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies May 14, 2015 Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Methods of Administration and Compositions in the Treatment of Parkinson's Disease - Patent Issuance Will Provide IP Protection for Lead Product Candidate Eltoprazine for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID) May 13, 2015 Amarantus Announces the Presentation of Data Showing MANF's Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting May 7, 2015 Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF May 5, 2015 Amarantus Granted European Union Orphan Drug Designation for MANF for the Treatment of Retinitis Pigmentosa April 29, 2015 More News

Company Information

Amarantus BioScience Holdings, Inc. 655 Montgomery Street Suite 900 San Francisco, CA 94111

c/o ICS Corporate Services SA 29 quai du Mont Blanc CH-1201 Geneva Switzerland

Read more:
Amarantus Bioscience Holdings Inc. (AMBS ... - InvestorsHub


Comments are closed.

Archives